Loading...
Market
Will lenacapavir be included in national HIV prevention programs in any African country by the end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from national health ministries in African countries
Story
Lenacapavir Injection Shows 100% Efficacy in PURPOSE-1 HIV Prevention Trial
Aug 8, 2024, 11:12 AM
A groundbreaking study has demonstrated the efficacy of lenacapavir, an antiviral drug administered as a twice-yearly injection, in preventing HIV among cisgender women. The PURPOSE-1 trial, involving more than 2,000 African women, reported that none of the participants contracted HIV after receiving lenacapavir. This study, published in the New England Journal of Medicine, highlights the potential of lenacapavir to overcome adherence challenges associated with daily oral pre-exposure prophylaxis (PrEP) and daily F/TAF. Dr. Rajesh Gandhi noted the trial's striking efficacy, suggesting a new era in HIV prevention. The injection maintains effective HIV prevention over 6 months.
View original story
Similar markets
South Africa • 25%
Uganda • 25%
Both countries • 25%
Neither country • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
United States • 25%
South Africa • 25%
India • 25%
Other • 25%